Optimind Pharma Announces Definitive Agreement for Proposed Change of Business with InterviewDesk

Core Viewpoint - Optimind Pharma Corp. has entered into a definitive share exchange agreement with InterviewDesk, marking a transition to a technology company focused on artificial intelligence, which constitutes a "Fundamental Change" under Canadian Securities Exchange policies [1][6]. Transaction Summary - The company will issue a total of 11,000,000 common shares post-consolidation and an additional 3,000,000 shares to InterviewDesk's principals over two years [4]. - Prior to the transaction's closing, the company will consolidate its existing shares at a ratio of one new share for approximately 3.66 old shares, resulting in 30,000,000 shares outstanding [5]. - The transaction requires shareholder approval at a future meeting [6]. Financing Details - The company plans to conduct a private placement of subscription receipts or shares at an issue price of $0.10, aiming to raise between $750,000 and $1,200,000 [10]. Management and Leadership - The resulting issuer's board will consist of four members, with two nominees from each company, and Rakesh Malhotra will remain as CFO [13]. - Pichumani Durairaj and Vasundhara Pichumani will serve as CEO and COO, respectively, bringing extensive experience in recruitment and operations [18][19]. About InterviewDesk - InterviewDesk, founded by former Amazon employee Pichumani Durairaj, focuses on automating the hiring process through its AI-driven platform, Creya AI, which aims to enhance recruitment efficiency [21][22]. - The platform has processed over 1 million assessments and is used by more than 100,000 global users, significantly reducing hiring time by up to 70% [23].